1986 Volume 32 Issue 4 Pages 529-533
During the period December 1, 1983 to June 1, 1985, 36 patients with advanced, recurrent and/or metastatic malignant tumor in the head and neck were given cisplatin and peplomycin. The overall cumulative response to this chemotherapy was 53%. However the response rate for squamous cell carcinoma was 67%. Although it was difficult to evaluate the actual and statistical significance of this anticancer drug in comparison with other chemotherapeutic agents, cisplatin seemed to be effective in treating head and neck squamous cell carcinoma in order to prolong of the survival rate. No significant side effects were detected in this study. From our results we wonder if a higher dosage may improve the currative ratio.
